Disease · MONDO_0002447

endometrial carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. endometrial carcinoma. Diseases, record MONDO_0002447. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002447

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: endometrial carcinoma; Open Targets
Open Targets ID: MONDO_0002447; Open Targets
Other names: carcinoma of endometrium, carcinoma of the endometrium, carcinoma, endometrial, malignant, endometrial cancer, endometrial carcinoma (disease), endometrium carcinoma; Open Targets
Disease Ontology: DOID:2871; Disease Ontology
NCI Thesaurus: C7558; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 13 of its 118 drugs, from ClinicalTrials.gov; Open Targets

Drugs118

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SACITUZUMAB GOVITECAN	CHEMBL3545262	Antibody drug conjugate	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 118

See all 118 drugs

Targets234

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PIK3CA	PI3-kinase class I	8	PI3-kinase class I inhibitor; PI3-kinase p110-alpha subunit inhibitor	Phase 2	https://conductscience.org/library/genes/5290	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	7	Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
PDCD1	Programmed cell death protein 1	7	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PGR	Progesterone receptor	6	Progesterone receptor agonist; Progesterone receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/5241	Drugs and targets
PIK3CD	PI3-kinase class I	6	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Phase 2	https://conductscience.org/library/genes/5293	Drugs and targets
PIK3CB	PI3-kinase class I	5	PI3-kinase class I inhibitor	Phase 2	https://conductscience.org/library/genes/5291	Drugs and targets
PIK3CG	PI3-kinase class I	5	PI3-kinase class I inhibitor	Phase 2	https://conductscience.org/library/genes/5294	Drugs and targets
PIK3R1	PI3-kinase class I	5	PI3-kinase class I inhibitor	Phase 2	https://conductscience.org/library/genes/5295	Drugs and targets
PIK3R2	PI3-kinase class I	5	PI3-kinase class I inhibitor	Phase 2	https://conductscience.org/library/genes/5296	Drugs and targets
PIK3R3	PI3-kinase class I	5	PI3-kinase class I inhibitor	Phase 2	https://conductscience.org/library/genes/8503	Drugs and targets

1 to 10 of 234

See all 234 targets

Trials111

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03884101	Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)	Phase 3	842	2024-10-16	Endometrial Neoplasms	LENVATINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00942357	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Phase 3	813	2018-12-19	Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7	CARBOPLATIN, CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00807768	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	Phase 3	601	2018-04-27	Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02501096	A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors	Phase 1/2	357	2023-07-20	Tumors	LENVATINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02454972	Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors	Phase 2	345	2021-11-22	Advanced Solid Tumors	LURBINECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT02807844	Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies	Phase 1/2	141	2021-08-11	Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma	SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04865289	Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study	Phase 3	130	2024-10-18	Endometrial Neoplasms	LENVATINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03395080	A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma	Phase 2	111	2023-06-09	Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma	DKN-01, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04590248	A Study of Adavosertib as Treatment for Uterine Serous Carcinoma	Phase 2	109	2023-08-14	Uterine Serous Carcinoma	ADAVOSERTIB	Its record names the disease	ClinicalTrials.gov
NCT03015129	A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer	Phase 2	80	2024-02-06	Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma, Recurrent	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 111

See all 111 trials

Comparisons in its trials21

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced a Serious Adverse Event (SAE)	230 of 420	84 of 411	831	NCT03884101	Trial comparisons
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Discontinued Study Intervention Due to an AE	203 of 420	80 of 411	831	NCT03884101	Trial comparisons
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Adverse Event (AE)	418 of 420	405 of 411	831	NCT03884101	Trial comparisons
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Immune-Related Adverse Event (irAE)	316 of 420	56 of 411	831	NCT03884101	Trial comparisons
Arm I (Cisplatin, Radiation Therapy, Paclitaxel, Carboplatin) vs Arm II (Paclitaxel and Carboplatin): Number of Participants With Recurrence, Progression or Death	132 of 370	139 of 366	736	NCT00942357	Trial comparisons
Arm I (Cisplatin, Radiation Therapy, Paclitaxel, Carboplatin) vs Arm II (Paclitaxel and Carboplatin): serious adverse events	78 of 346	61 of 361	707	NCT00942357	Trial comparisons
Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Recurrence or Death Events at Primary Analysis	44 of 301	43 of 300	601	NCT00807768	Trial comparisons
Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Death Events	39 of 301	37 of 300	601	NCT00807768	Trial comparisons
Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): serious adverse events	9 of 283	32 of 290	573	NCT00807768	Trial comparisons
Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: deaths from any cause	34 of 74	25 of 56	130	NCT04865289	Trial comparisons

1 to 10 of 21

See all 21 comparisons in its trials

Papers from its trials118

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39591551	RESULT	1	PubMed
35658948	RESULT	1	PubMed
29330207	RESULT	1	PubMed
29302014	RESULT	1	PubMed
29214032	RESULT	1	PubMed
29097493	RESULT	1	PubMed
28862931	RESULT	1	PubMed
28709704	RESULT	1	PubMed
28489510	RESULT	1	PubMed
28471727	RESULT	1	PubMed

1 to 10 of 118

See all 118 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002447

GET https://conductscience.org/api/diseases/v1/MONDO_0002447/drugs?page=2

API reference For AI assistants